Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fusion AntibodiesLSE:FAB -2.27%32 PB Ratio is 17.92 as of Jul. 15, 2026, which is 351% above its 10-year median of 3.97. GuruFocus rates LSE:FAB with a GF Score™ of 32/100 and a GF Value™ of £0.04 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,228 Biotechnology companies, Fusion Antibodies ranks worse than 92.83% on this metric.
The historical rank and industry rank for Fusion Antibodies's PB Ratio or its related term are showing as below:
LSE:FAB'
s PB Ratio Range Over the Past 10 Years
Min: 0.74 Med: 3.97 Max: 32.08
Current: 17.91
During the past 11 years, Fusion Antibodies's highest PB Ratio was 32.08. The lowest was 0.74. And the median was 3.97.
LSE:FAB's PB Ratio is ranked worse than 92.83% of 1228
companies
in the Biotechnology industry
Industry Median: 2.895
vs LSE:FAB: 17.91
During the past 12 months, Fusion Antibodies's average Book Value Per Share Growth Rate was -45.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -65.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -52.40% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -8.60% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Fusion Antibodies was 234.00% per year. The lowest was -65.20% per year. And the median was -15.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Fusion Antibodies PB Ratio Related Terms
Fusion Antibodies PB Ratio Historical Data
* Premium members only.
The historical data trend for Fusion Antibodies's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Fusion Antibodies's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fusion Antibodies PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fusion Antibodies's PB Ratio distribution charts can be found below:
* The bar in red indicates where Fusion Antibodies's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Fusion Antibodies (LSE:FAB) has a PB Ratio of 17.92 as of Jul. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Fusion Antibodies and its competitors. This is 351% above median its historical median of 3.97. Over the past decade, Fusion Antibodies' PB Ratio has ranged from 0.74 to 32.08. According to the industry distribution chart, Fusion Antibodies ranks #1140 out of 1228 companies in the Biotechnology industry, placing it in the top 92.8%.
Is Fusion Antibodies' PB Ratio too high?
Fusion Antibodies' current PB Ratio of 17.92 is 351% above median its 10-year median of 3.97. Over the past 10 years, this metric has ranged from a low of 0.74 to a high of 32.08. The Biotechnology industry median PB Ratio is 2.90. Fusion Antibodies' value of 17.92 is 519% above this industry median. Based on the distribution chart, Fusion Antibodies ranks #1140 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Fusion Antibodies has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fusion Antibodies' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fusion Antibodies ranks #1140 out of 1228 companies for PB Ratio. This places Fusion Antibodies in the lower half of its industry. The industry median PB Ratio is 2.90. Fusion Antibodies' value of 17.92 is 519% above this benchmark. Historically, Fusion Antibodies' own PB Ratio has ranged from 0.74 to 32.08 over the past decade. While the company's 10-year median is 3.97 vs. the industry median of 2.90, Fusion Antibodies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.90, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fusion Antibodies's current PB Ratio of 17.92 is 519% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Fusion Antibodies and its competitors. For the Biotechnology industry, the median PB Ratio is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fusion Antibodies's current PB Ratio is 17.92, which is 351% above median its own 10-year median of 3.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fusion Antibodies stock overvalued right now?
Based on GuruFocus' analysis, Fusion Antibodies (LSE:FAB) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.04, compared to a current price of £0.11 — trading 168.8% above its estimated fair value. The current PB Ratio is 17.92, which is 351% above median its 10-year median of 3.97 and 519% above the Biotechnology industry median of 2.90. Fusion Antibodies' overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Fusion Antibodies (LSE:FAB), the current PB Ratio is 17.92 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fusion Antibodies (LSE:FAB) Overvalued in 2026?
Based on GuruFocus' analysis, Fusion Antibodies stock appears to be overvalued.
The current stock price of £0.11 is trading 168.8% above its estimated GF Value™ of £0.04.
GuruFocus considers Fusion Antibodies to be Significantly Overvalued.
Key valuation signals for LSE:FAB:
PB Ratio: 17.92 (351% above median its 10-year median of 3.97)
GF Value™: £0.04 vs. price of £0.11 (168.8% above fair value)
Industry Position: 519% above the Biotechnology median (#1140 of 1228)
No single metric tells the full story. See the LSE:FAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.
32GF Score
Get the complete analysis for LSE:FAB
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:FAB has been successfully added to your 
